Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Posts 10-Percent Q2 Organic Revenue Growth as Profit Rises 3 Percent

NEW YORK (GenomeWeb News) – Qiagen yesterday said second-quarter revenues rose 13 percent, 10 percent of which was organic growth, while the company’s net profit increased 3 percent.
Receipts for the second quarter increased to $113.2 million from $100.4 million in the same quarter last year. Approximately 10 percent of this was organic and acquisitions contributed about 3 percent, Qiagen said. 
The company said that these results were driven by a 14-percent spike in its consumables business, 11 percent of which was organic. Organic instrumentation sales increased 2 percent.
Sales in North America grew approximately 9 percent and represented about 45 percent of Qiagen’s overall business, while European sales grew 14 percent and represented about 45 percent of overall sales. Qiagen said that net sales in Asia grew by 30 percent, driven primarily by strong demand in China.
The company spent about $10.2 million on R&D in the second quarter, up 17 percent from $8.7 million in the comparable period last year.
Qiagen’s net income for the second quarter rose slightly to $14.2 million from $13.8 million in Q2 2005.

As of June 30, Qiagen had approximately $473 million in cash and cash equivalents.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.